Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aranidipine (MPC1304) 是一种钙通道拮抗剂,具有强效和持久的抗高血压作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
5 mg | ¥ 488 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,390 | 现货 | ||
50 mg | ¥ 2,230 | 现货 | ||
100 mg | ¥ 3,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 595 | 现货 |
产品描述 | Aranidipine (MPC1304) (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects. |
体外活性 | In myocytes, aranidipine (10 nmol/l to 1 micromol/l) concentration-dependently decreased T-type and L-type Ca(2+) currents. Aranidipine (1 micromol/l) had little effect on K(+) currents. In the sinoatrial node, 0.1 micromol/l aranidipine increased cycle length and decreased +V(max) and the slope of the phase 4 depolarization [1]. |
体内活性 | At 1 and 6 h after oral administration of MPC-1304 (10 mg/kg) in spontaneously hypertensive rats (SHR), there was significant decrease (48%) in the number of [3H](+)-PN 200-110 binding sites (Bmax) in myocardial membranes compared to control values. The in vivo specific binding of [3H](+)-PN 200-110 in particulate fractions of aorta of SHR was significantly reduced (74.8 and 37.9%, respectively) at 1 and 6 after oral administration of MPC-1304 (3 mg/kg), while the myocardial [3H](+)-PN 200-110 binding was decreased only at 1 h later [2]. |
别名 | 阿雷地平, MPC1304 |
分子量 | 388.37 |
分子式 | C19H20N2O7 |
CAS No. | 86780-90-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (57.93 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5749 mL | 12.8743 mL | 25.7486 mL | 64.3716 mL |
5 mM | 0.515 mL | 2.5749 mL | 5.1497 mL | 12.8743 mL | |
10 mM | 0.2575 mL | 1.2874 mL | 2.5749 mL | 6.4372 mL | |
20 mM | 0.1287 mL | 0.6437 mL | 1.2874 mL | 3.2186 mL | |
50 mM | 0.0515 mL | 0.2575 mL | 0.515 mL | 1.2874 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aranidipine 86780-90-7 Membrane transporter/Ion channel Metabolism Calcium Channel inhibit MPC-1304 MPC 1304 Inhibitor Ca channels 阿雷地平 Ca2+ channels MPC1304 inhibitor